COMPANY PROFILE / CELL CULTURE TECHNOLOGY
WuXi Biologics
A Chinese one-stop CDMO that takes antibodies all the way from research to manufacture
WuXi Biologics is a contract service company for biopharmaceuticals, headquartered in Wuxi, China, and listed on the Hong Kong Stock Exchange. It calls itself a "CRDMO", taking on research, development and manufacturing as one integrated service: a single company receives an antibody gene from the customer, builds a CHO cell line, develops the culture process and carries out commercial manufacture. Revenue in the first half of 2026 was RMB 11.8 billion (up 18.4% year on year), and 58.4% of it came from customers in North America. At the same time, it sold a vaccine plant in Ireland and a drug product plant in Germany in 2025, and in 2026 decided to sell its purification materials subsidiary. This profile sets out what the company is putting into cell culture, who it works with and where it is heading, using only its statutory disclosures to the Hong Kong exchange.
- WuXi Biologics in 30 seconds, and where it stands in cell culture
- The logo and how the name is written
- Where the company sits in the cell culture landscape
- Scale
- Resources committed to cell culture
- What it has done so far
- What comes next
- What the company is aiming for in cell culture
- Map of cell culture partnerships
- Technologies, products and services
- The risks this company carries
- Glossary, references and claim-to-source audit
1. WuXi Biologics in 30 seconds, and where it stands in cell culture
(Cayman) Inc.Incorporated in the Cayman Islands; it also has an official Chinese name
ChinaNo. 108, Meiliang Road, Mashan
2269ADC subsidiary WuXi XDC is also listed in Hong Kong (2268)
(self-styled CRDMO)Sale of its purification materials subsidiary under way
Companies involved in cell culture fall into three broad types: contract development and manufacturing organisations (CDMOs), suppliers of equipment, consumables and media, and developers of cell and regenerative therapies. WuXi Biologics is a CDMO. "Cell culture" has two meanings, (1) growing animal cells to make antibodies and other proteins, and (2) cell therapy, where the cells themselves are the product, and the company works only in the first Sourced. Contract manufacturing of cell therapies does not appear in the service lists on its website or in its annual report. What sets it apart is that, where other CDMOs come in at the manufacturing stage, it brings customers in at the antibody discovery (research) and cell line (development) stages: 44.8% of revenue in the first half of 2026 came from services before the application to start clinical trials (IND).
2. The logo and how the name is written
The WuXi Biologics logo is a trademark of the company. We have not recreated it with generated imagery;
the logo image (SVG) shown at the top of the official website's pages is placed here as img/wuxi_biologics_logo.svg.
A note on names: the listed company's legal name is WuXi Biologics (Cayman) Inc., and it also has an official Chinese name. Japanese-language coverage uses several renderings, including a Japanese reading of the Chinese name and a katakana transliteration; this series uses the English name throughout. The annual report's related-party transactions mention other listed group companies bearing the WuXi name, such as "WuXi AppTec" and "STA", but these are separate companies from WuXi Biologics. WuXi XDC, which provides contract ADC services, is a subsidiary of WuXi Biologics.
Official site: https://www.wuxibiologics.com/3. Where the company sits in the cell culture landscape
The company reports two segments: Biologics (research, development and manufacture of antibodies and other biologics) and XDC (contract services for ADCs and other conjugates, through its subsidiary WuXi XDC) Sourced. Cell culture is directly involved in Biologics. In XDC the antibody part is also made by cell culture, but the work centres on the conjugation step, a chemical reaction.
4. Scale
Almost all of the revenue comes from contract work on antibodies and other biologics, so the size of the company as a whole is close to the size of its cell culture business Sourced. Amounts are in renminbi (RMB million).
| Measure (RMB million) | 2023 | 2024 | 2025 | H1 2026 |
|---|---|---|---|---|
| Revenue | 17,034.3 | 18,675.4 | 21,790.0 | 11,787.2 |
| Gross margin | 40.1% | 41.0% | 46.0% | 46.2% |
| Net profit attributable to owners of the parent | 3,399.7 | 3,356.1 | 4,908.3 | 2,439.8 |
| R&D expense | - | 766.4 | 853.4 | 430.2 |
| Purchases of property, plant and equipment (cash paid) | - | 3,929.6 | 3,685.1 | - |
| H1 2026 | Amount (RMB million) | Share |
|---|---|---|
| Segment: Biologics (external revenue) | 8,105.3 | 68.8% |
| Segment: XDC (external revenue) | 3,681.9 | 31.2% |
| Region: North America | 6,887.5 | 58.4% |
| Region: Europe | 1,990.2 | 16.9% |
| Region: China | 1,955.3 | 16.6% |
| Region: Other (Singapore, Japan, South Korea and others) | 954.2 | 8.1% |
Segment shares are our calculation against total external revenue (RMB 11,787.2 million). Regional shares are the company's disclosed figures.
WuXi Biologics does not disclose its total bioreactor capacity (in litres) in its annual or interim reports Not yet confirmed. Individual facilities are disclosed (three 5,000 L single-use bioreactors at MFG20 in Hangzhou, 12,000 L scale at MFG7 in Ireland, six 6,000 L single-use bioreactors at MFG11 under construction in the U.S., and so on), but no total is given, so this article does not compare its capacity with other companies'. The US$25.1 billion backlog also includes US$12.4 billion of potential future milestone fees, and the company itself notes that "the timing and probability of potential milestone fee realization may vary, as it is contingent upon project success and development progress".
5. Resources committed to cell culture
As in every profile in this series, we check four kinds of resource (people, money, external investments and acquisitions, and ties with universities and research institutes) and show whether each could be confirmed from primary sources.
| Type of resource | What could be confirmed | Status |
|---|---|---|
| People | 14,705 employees, including 5,180 scientists (end of June 2026). The research arm (Global Biologics Research) has about 800 scientists. The cell line construction platform can handle 200 integrated CMC projects a year and has delivered more than 1,400 cell lines | Confirmed |
| People (sites) | China (Wuxi, Fengxian in Shanghai, Hangzhou, Hebei, Suzhou, Chengdu and elsewhere), Ireland, the U.S. (Cranbury, New Jersey, and Worcester, Massachusetts, under construction) and Singapore (under construction). Fifteen GMP-certified manufacturing facilities | Confirmed |
| Money (capital expenditure) | RMB 3,685.1 million spent on property, plant and equipment in 2025. The amount for cell culture facilities alone is | Not disclosed |
| Money (R&D) | RMB 853.4 million in 2025 (about 3.9% of revenue) and RMB 430.2 million in H1 2026 (up 25.2% year on year). The amount for cell culture technology alone is | Not disclosed |
| External investments and acquisitions | Stake in Shanghai Duoning Biotechnology, which sells serum-free media and single-use products, raised from 17.36% to 19.75% (2025, RMB 60 million in cash). Subsidiary WuXi XDC acquired about 60% of BioDlink (H1 2026) | Confirmed |
| Divestments | Vaccine plant in Ireland sold to MSD International (US$437 million, completed March 2025); drug product plant in Germany sold (2025); purification materials maker Bestchrom to be sold (completion expected December 2026) | Confirmed |
| University and research ties | No joint research with universities or research institutes in cell culture is mentioned in the annual or interim report (receipt of research grants is mentioned) | Not confirmed |
According to the annual report, WuXi Biologics bought about RMB 128.28 million of materials from Shanghai Duoning in 2025 (about RMB 88.83 million in 2024; purchases from Duoning's subsidiaries are recorded separately). Duoning's business is described as the sale of serum-free media and single-use products and the production of, and services for, formulations, and WuXi Biologics holds 19.75% of it and has a director on its board Sourced. In animal cell culture, the composition of the medium and the resin of the single-use bags affect how cells grow and the quality of the antibody. A CDMO that both invests in and buys from a media and consumables maker can secure stable supply while sourcing materials suited to its own process development. Meanwhile, the company has decided to sell Bestchrom, its subsidiary making purification materials (chromatography resins), which suggests a preference for keeping materials at the level of an investment and a supply relationship rather than owning a whole materials business Not yet confirmed.
6. What it has done so far
| When | What happened | Why it matters |
|---|---|---|
| Since 2017 | 49 regulatory inspections by authorities in various countries (as of the end of June 2026, 23 of them by the EMA and the FDA), with no critical findings disclosed | The basis for a China-based contractor to win approval in Europe and the U.S. |
| November 2023 | ADC subsidiary WuXi XDC listed on the Hong Kong exchange | The conjugates business moved into a separate company |
| March 2025 | Sale of the vaccine plant in Ireland to MSD International completed (US$437 million) | Narrowing the business away from contract vaccine work |
| 2025 | Drug product plant in Germany sold to an independent third party. Commercial PPQ completed on three 5,000 L single-use bioreactors at MFG20 in Hangzhou (described by the company as "Asia's first 5,000L DS scale-up line utilizing SUBs") | Commercial manufacture in large single-use bioreactors |
| 2025 | Launch of "WuXia293Stable", an expression platform using HEK293 cells, and "WuXia TrueSite", a fourth-generation cell line platform. Stake in Duoning raised to 19.75% | A way to handle molecules that are hard to make in CHO cells |
| 2025 | Three 1,000 L single-use bioreactors added at MFG6 in Ireland, taking capacity from 3,000 L to 6,000 L. Memorandum of understanding with the Qatar Free Zones Authority on establishing a site | More capacity outside China |
| H1 2026 | First GMP campaign using HEK293 perfusion culture completed, supporting a customer's U.S. IND approval. First GMP run at MFG17 in Fengxian, Shanghai. MFG8 in Hebei passed a U.S. FDA pre-license inspection | New cell types and culture modes in real production |
| H1 2026 | WuXi XDC acquired about 60% of BioDlink | More manufacturing capacity for contract ADC work |
| July 2026 | Agreement signed with an independent third party to sell Bestchrom, the purification materials subsidiary (completion expected December 2026) | Exit from the materials business |
7. What comes next
by 202768 INDs supported in H1 2026
under constructionSix 6,000 L single-use bioreactors. Cranbury moving to commercial work too
topped outAbout 100 million units a year expected. A modular DS plant is being designed
The following plans related to cell culture have been announced Sourced.
- United States: MFG11 in Worcester is under construction as planned. At MFG18 in Cranbury, New Jersey, the first commercial PPQ is under way, which the company describes as a milestone in expanding from clinical to commercial manufacturing.
- Ireland: three new large-scale manufacturing projects won so far in 2026, with technology transfer begun.
- Singapore: a "CRDMO hub" with a drug product plant (topped out) and a modular drug substance plant (being designed).
- Direction: the company says it will continue to invest in next-generation technologies and new modalities and strengthen its global manufacturing network (the outlook section of the Interim Results Announcement).
None of the following appears in the primary sources consulted Not yet confirmed.
A numerical revenue outlook for full-year 2026 (the Interim Results Announcement gives none); total bioreactor capacity; the investment in each new plant; when the new plants in Singapore and the U.S. will start operating; and any plan to enter contract cell therapy work. Figures and plans that appear in press coverage are not used in this article.
8. What the company is aiming for in cell culture
This section goes beyond what the company says directly. It sets out inferences that can be drawn from primary sources, each with its basis.
| What can be read | Primary evidence behind it | Category |
|---|---|---|
| The key battleground is to win customers at the cell line and process development stage and carry them through to manufacturing | The company's "Follow and Win the Molecule" strategy; 44.8% of H1 2026 revenue came from pre-IND services, and 525 of its 1,064 integrated projects are preclinical | Inference |
| In culture facilities it competes on "single-use bioreactors plus high-productivity processes" rather than "big stainless-steel tanks" | The company says its continuous process "WuXiUP" achieves productivity comparable to 10,000 to 20,000 L stainless-steel bioreactors using 1,000 to 2,000 L single-use bioreactors. New plants also use 5,000 L and 6,000 L single-use bioreactors | Inference |
| It is adding sites outside China to answer customers' supply-chain concerns | The "Global Dual Sourcing" strategy, the expansion in Ireland, the U.S. and Singapore, and the statement that it "will continue to monitor tariffs and geopolitical developments" | Inference |
| It is expanding into areas around antibodies (multispecifics, ADCs, peptides) and is not moving towards cell therapy | Under "New Growth Drivers" it lists multispecific antibodies, peptides, microbial, HEK293 and ADCs, but not cell therapy. The vaccine plant has been sold | Inference |
| It uses HEK293 cells for molecules that are hard to make in CHO cells | The annual report says the HEK293 platform addresses challenges "by resolving truncation and glycosylation issues" for complex molecules. First GMP campaign in perfusion culture in H1 2026 | Sourced |
The Interim Results Announcement gives "typical" service revenue for each project stage: US$3–8 million per project for preclinical and US$4–6 million for Phase 1 and 2, against US$20–50 million for Phase 3 and US$50–100 million a year for a single commercial project (estimated at peak) Sourced. Holding a large number of preclinical projects, in other words, is sowing the seeds of large manufacturing revenue for the day some of them reach Phase 3 or commercial supply. Phase 3 and commercial projects, 74 and 25 at the end of 2025, had grown to 78 and 28 by the end of June 2026. The company that first built the cell line and the culture process is well placed to be trusted with the manufacturing that follows. This article reads that as the design principle of the company's cell culture business Not yet confirmed.
9. Map of cell culture partnerships
10. Technologies, products and services
| Category | What it covers (per the annual report and Interim Results Announcement) | Type of cell culture |
|---|---|---|
| Cell line development | Its own CHO cell line platform, "WuXia". The fourth-generation "WuXia TrueSite" uses targeted integration of the gene, and the company cites average antibody titres above 8.0 g/L (up to 12 g/L). Adopted in more than 70 projects since its 2025 launch | (1) Biologics |
| Culture process (continuous) | "WuXiUP": 1,000 to 2,000 L single-use bioreactors with productivity comparable to 10,000 to 20,000 L stainless-steel bioreactors. Validated on more than 65 molecules, at 20 to 120 g/L | (1) Biologics |
| Culture process (intensified fed-batch) | "WuXiUI": fed-batch culture combined with intermittent perfusion, with 3 to 8 times the productivity of conventional fed-batch (the company says this has been demonstrated with more than 50 cell lines) | (1) Biologics |
| HEK293 cells | "WuXia293Stable": human-derived cells that express complex molecules hard to make in CHO cells. First GMP campaign in perfusion culture in H1 2026 | (1) Biologics |
| Digital twin | "PatroLab": predicting process performance and reducing risk | (1) (process control) |
| Manufacturing | Clinical and commercial manufacture of drug substance (DS) and drug product (DP). Fifteen GMP-certified facilities | (1) Biologics |
| Cell therapy | Not in the service list | (2) not offered |
In continuous (perfusion) culture such as WuXiUP, the cells stay in the tank while the medium is replaced continuously. The membrane that separates cells from the culture fluid (such as a hollow-fibre filter) then becomes the heart of the process, and it must resist fouling, adsorb little protein and stay sterile over long periods. And the higher the cell density, the greater the relative effect on cell growth of trace substances that leach out of the film of single-use bags (leachables) Not yet confirmed (this paragraph is a general explanation of continuous culture; WuXi Biologics has not disclosed the materials of the membranes or bags it uses). The more widely this "small tank, large output" approach spreads, the more the demands on materials shift from quantity to consistency of quality.
11. The risks this company carries
| Risk | Substance | Category |
|---|---|---|
| Tariffs and geopolitics | The annual report says the company "will continue to monitor tariffs and geopolitical developments, and operate in accordance with the applicable laws and regulations of all jurisdictions where it has business operations". With 58.4% of revenue from North American customers (H1 2026), the business is exposed to U.S.-China relations | Sourced |
| Uncertainty of milestone revenue | US$12.4 billion of the US$25.1 billion backlog is potential future milestones, and the company itself notes that timing and probability depend on the success of customers' projects | Sourced |
| Customer concentration | The top five customers accounted for 26.1% of revenue in 2025 (29.1% in 2024) | Sourced |
| Currency | In H1 2026 a weaker U.S. dollar and euro led to unrealised foreign exchange losses, lowering the net margin | Sourced |
| Conditions for completing divestments | Completion of the Bestchrom sale is expected in December 2026. Of the proceeds from the Irish vaccine plant, US$30 million will be received after a warranty period ending in October 2026 | Sourced |
| Staying out of cell therapy | If the contract cell therapy market grows, the company will not capture that growth. On the other hand, its focus on antibodies can also be a strength | Inference |
12. Glossary
- CRDMO
- A name for a business that takes on research, development and manufacturing as one integrated contract service. WuXi Biologics uses it to describe itself. See also our explainer on CDMOs.
- CHO cells
- Cells derived from Chinese hamster ovary. The animal cells most widely used to produce antibody drugs.
- HEK293 cells
- Cells derived from human embryonic kidney. They readily add human-type glycans and other modifications and are used to produce proteins that are hard to make in CHO cells.
- Perfusion (continuous) culture
- A culture method in which cells are held in the tank while the medium is continuously replaced, keeping cell density high for a long time.
- Fed-batch culture
- A culture method in which nutrients are added during the run and the whole batch is harvested after a set period. The standard approach for antibody production.
- Single-use bioreactor
- A culture tank that uses a disposable plastic bag, removing the need for cleaning and sterilisation. See our explainer on single-use systems.
- IND
- Investigational New Drug application, the application to begin clinical trials. "Pre-IND" refers to the preclinical stage.
- PPQ
- Process performance qualification. The step before commercial manufacture in which actual production runs show that the process consistently meets quality standards.
- ADC
- Antibody-drug conjugate. A medicine in which a drug is attached to an antibody.
- Serum-free medium
- A culture medium containing no animal serum. Its composition is consistent, which makes quality control easier in drug manufacturing. See our explainer on cell culture media.
13. References
- WuXi Biologics (Cayman) Inc. 2025 Annual Report (Chairman's and CEO's statements dated 24 March 2026). Five-year financial highlights, business review (WuXia, HEK293, MFG20, Ireland, the U.S., Singapore, Chengdu and Qatar), sale of the vaccine plant and the German drug product plant, R&D expense, employees, share of the top five customers, the investment in and transactions with Duoning, the reference to tariffs and geopolitics, and investing cash flows. https://cdn.wuxibiologics.com/en/wp-content/uploads/2026042900764.pdf
- WuXi Biologics (Cayman) Inc. Interim Results Announcement for the six months ended June 30, 2026. H1 2026 revenue and profit, project numbers and typical revenue by stage, backlog, cell line and culture process platforms, manufacturing milestones, new growth drivers, revenue by region, stage and segment, R&D expense, the Bestchrom sale, and outlook. https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260923170523480.pdf
- WuXi Biologics (Cayman) Inc. 2026 Interim Report. Head office address (Wuxi), registered office (Cayman Islands), 14,705 employees and 5,180 scientists. https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260923121332982.pdf
- WuXi Biologics (Cayman) Inc. Official website (used to check the service list, and source of the logo image). https://www.wuxibiologics.com/
14. Claim-to-source audit
| Claim in the article | Category | Source |
|---|---|---|
| Legal name, Chinese name, Cayman Islands incorporation, head office address (Wuxi) and Hong Kong listing (2269) | Sourced | Reference 3 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260923121332982.pdf |
| 2023 to 2025 revenue, gross margin and net profit, R&D expense and purchases of property, plant and equipment | Sourced | Reference 1 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026042900764.pdf |
| H1 2026 revenue, profit and R&D expense; revenue by region, stage and segment | Sourced | Reference 2 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260923170523480.pdf |
| Segment shares (Biologics 68.8%, XDC 31.2%) and R&D at about 3.9% of revenue | Our calculation | Calculated in this article from the amounts in references 1 and 2 |
| Backlog of US$25.1 billion (including US$12.4 billion of milestones) and the company's note on realising it | Sourced | Reference 2 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260923170523480.pdf |
| 14,705 employees and 5,180 scientists; about 800 in the research arm | Sourced | References 2 and 3 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260923121332982.pdf |
| Performance and track record of WuXia, WuXia TrueSite, WuXiUP, WuXiUI and PatroLab | Sourced | Reference 2 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260923170523480.pdf |
| Purpose of the HEK293 platform (annual report) and the first GMP campaign in H1 2026 | Sourced | References 1 and 2 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026042900764.pdf |
| MFG20 (three 5,000 L single-use bioreactors), MFG6 and MFG7 in Ireland, MFG11 (six 6,000 L), Chengdu and the Qatar MoU | Sourced | Reference 1 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026042900764.pdf |
| Sale of the vaccine plant to MSD International (US$437 million, completed 31 March 2025) and sale of the German drug product plant | Sourced | Reference 1 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026042900764.pdf |
| The stake in Duoning (19.75%), its business and the materials purchased | Sourced | Reference 1 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026042900764.pdf |
| Bestchrom's business and sale (completion expected December 2026); acquisition of about 60% of BioDlink | Sourced | Reference 2 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260923170523480.pdf |
| Development support for Earendil Labs, HanchorBio and Guizhou Sinorda | Sourced | Reference 2 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260923170523480.pdf |
| 49 regulatory inspections (23 by the EMA and FDA), 15 GMP-certified facilities, MFG8 passing an FDA pre-license inspection, first GMP run at MFG17 | Sourced | Reference 2 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260923170523480.pdf |
| Share of revenue from the top five customers, and the statement about monitoring tariffs and geopolitics | Sourced | Reference 1 https://cdn.wuxibiologics.com/en/wp-content/uploads/2026042900764.pdf |
| 34 PPQs in 2026, capacity to support 300 INDs a year by 2027, and plans in the U.S., Ireland and Singapore | Not yet confirmed | Reference 2. Company plans https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260923170523480.pdf |
| Contract cell therapy work is not offered as a service | Sourced | The service list in reference 4 and the business review in reference 1 https://www.wuxibiologics.com/ |
| Total bioreactor capacity, investment in and start-up timing of each new plant, and a numerical outlook for full-year 2026 | Not yet confirmed | None appears in references 1 or 2, and this article makes no estimate |
| Joint research with universities and research institutes in cell culture | Not yet confirmed | Not in references 1 or 2. This article does not conclude that none exists https://cdn.wuxibiologics.com/en/wp-content/uploads/2026042900764.pdf |
| The three types (CDMO; tools, consumables and media; cell and regenerative therapy) | Our calculation | Our own classification. Companies shown are examples from the 20 in this series |
| The reading that the company wins customers at the development stage and carries them through to manufacturing | Inference | This article's interpretation of the strategy name, revenue by stage and typical revenue |
| The reading that it competes on single-use bioreactors plus high-productivity processes | Inference | This article's interpretation of the WuXiUP description and the equipment in new plants |
| The reading that it is adding sites outside China to answer supply-chain concerns | Inference | This article's interpretation of the Global Dual Sourcing strategy and the overseas expansion |
| The reading that it is expanding around antibodies and not moving towards cell therapy | Inference | This article's interpretation of the list of new growth drivers |
| The reading that it keeps materials at the level of an investment and supply relationship rather than owning a materials business | Not yet confirmed | This article's interpretation of the Duoning investment and the Bestchrom sale |
| The risk of staying out of cell therapy | Inference | This article's interpretation |
| The view that membrane and bag materials become critical in continuous culture | Not yet confirmed | A general explanation by this article, not based on the company's disclosures |
Last updated 24 September 2026 / Troy Technical
Every figure in this article comes from the annual report, interim report and interim results announcement published by WuXi Biologics (Cayman) Inc. under the rules of the Hong Kong Stock Exchange. No research-firm estimates or press-based figures have been used. Passages marked "Inference" are this article's interpretation of primary sources, not statements made by the company.